Inhibikase Therapeutics (IKT) Cash & Equivalents (2020 - 2025)
Historic Cash & Equivalents for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to $38.3 million.
- Inhibikase Therapeutics' Cash & Equivalents rose 408971.62% to $38.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.3 million, marking a year-over-year increase of 408971.62%. This contributed to the annual value of $56.5 million for FY2024, which is 51636.09% up from last year.
- As of Q3 2025, Inhibikase Therapeutics' Cash & Equivalents stood at $38.3 million, which was up 408971.62% from $77.7 million recorded in Q2 2025.
- Over the past 5 years, Inhibikase Therapeutics' Cash & Equivalents peaked at $77.7 million during Q2 2025, and registered a low of $913420.0 during Q3 2024.
- For the 5-year period, Inhibikase Therapeutics' Cash & Equivalents averaged around $26.6 million, with its median value being $14.9 million (2023).
- Per our database at Business Quant, Inhibikase Therapeutics' Cash & Equivalents soared by 60152563.9% in 2021 and then crashed by 9408.58% in 2023.
- Quarter analysis of 5 years shows Inhibikase Therapeutics' Cash & Equivalents stood at $40.8 million in 2021, then crashed by 82.36% to $7.2 million in 2022, then grew by 27.5% to $9.2 million in 2023, then skyrocketed by 516.36% to $56.5 million in 2024, then tumbled by 32.25% to $38.3 million in 2025.
- Its Cash & Equivalents stands at $38.3 million for Q3 2025, versus $77.7 million for Q2 2025 and $73.4 million for Q1 2025.